Albo Says Uncertain Times Ahead & The Scientist Behind Ozempic Answers Your Questions

They started as a treatment for diabetes, but GLP-1 medications like Ozempic and Wegovy have quickly become the most talked-about drugs in modern medicine.

With two-thirds of Australians now living with obesity, the shift from lifestyle-only messaging to pharmaceutical solutions is accelerating, but is it just a new form of diet culture, or a genuine medical breakthrough?

Today, we get rare access to one of the original pioneers of the science. Professor Lotte Bjerre Knudsen, Chief Scientific Advisor at Novo Nordisk, joins us to answer your questions.

Plus, Lotte addresses the headlines regarding side effects and why the FDA recently removed a major warning from the label.

🗞️ HEADLINES

• Anthony Albanese tells Australians to go about our lives but only buy the fuel and diesel needed
• The WA government has declared emergency powers allowing them to force fuel companies to share details on the supply chain
• Donald Trump has attended the US Supreme Court to hear arguments about birthright citizenship as he posts about Iran asking for a ceasefire
• Jackie O's friend and podcast co-host Gemma O'Neil has defended her decision to withdraw from the public eye

📩 GET IN TOUCH

Got a story, news tip-off, feedback or dilemma?

Send us a voice note or email us at thequicky@mamamia.com.au

🎙️ CREDITS

Hosts: Taylah Strano & Claire Murphy

Guest: Professor Lotte Bjerre Knudsen, Chief Scientific Advisor at Novo Nordisk

Group Executive Producer: Ilaria Brophy

Audio Producer: Lu Hill

Support independent women's media

Check out The Quicky Instagram here and our TikTok here

Discover more Mamamia podcasts here

Did you know some of our shows are now in video on the Apple Podcast app? Make sure your phone is up to date and check it out here!

Mamamia acknowledges the traditional owners of the land on which we have recorded this podcast.

Become a Mamamia subscriber: https://www.mamamia.com.au/subscribe

See omnystudio.com/listener for privacy information.